LY-2109761

LY-2109761

Identifiers
IUPAC name 4-[2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxyethyl]morpholine
CAS Number	700874-71-1  Y
PubChem CID	11655119
UNII	DV3HD37UBK
CompTox Dashboard (EPA)	DTXSID30470111
Chemical and physical data
Formula	C26H27N5O2
Molar mass	441.535 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CC2=C(C(=NN2C1)C3=CC=CC=N3)C4=C5C=CC(=CC5=NC=C4)OCCN6CCOCC6
InChI InChI=1S/C26H27N5O2/c1-2-9-27-22(4-1)26-25(24-5-3-11-31(24)29-26)21-8-10-28-23-18-19(6-7-20(21)23)33-17-14-30-12-15-32-16-13-30/h1-2,4,6-10,18H,3,5,11-17H2 Key:IHLVSLOZUHKNMQ-UHFFFAOYSA-N

LY-2109761 is a synthetic compound which acts as a potent and selective inhibitor for the growth factor receptor TGF beta receptor 1. It is used for research into conditions such as pulmonary fibrosis and cancer. ^{[1] [2]}

See also

• Galunisertib
• GW788388

References

1. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, et al. (April 2008). "LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis". Molecular Cancer Therapeutics. 7 (4): 829–840. doi:10.1158/1535-7163.MCT-07-0337. PMC   3088432 . PMID   18413796.
2. Tan QY, Cheng ZS (2018). "TGFβ1-Smad Signaling Pathway Participates in Interleukin-33 Induced Epithelial-to-Mesenchymal Transition of A549 Cells". Cellular Physiology and Biochemistry. 50 (2): 757–767. doi: 10.1159/000494241 . PMID   30308508. S2CID   52966340.